BioCentury
ARTICLE | Clinical News

Ravicti glycerol phenylbutyrate regulatory update

October 5, 2015 7:00 AM UTC

EMA’s CHMP recommended approval of Ravicti glycerol phenylbutyrate from Horizon as an adjunctive therapy for chronic management of patients aged >=2 months with urea cycle disorders (UCDs). In Februar...